Literature DB >> 21769450

Perifosine as potential anti-cancer agent inhibits proliferation, migration, and tube formation of human umbilical vein endothelial cells.

Feng Ze Wang1, Hong Rong Fei, Xiao Qian Li, Renjiu Shi, De Cai Wang.   

Abstract

Targeting angiogenesis is considered an effective strategy for treating the expansion and metastasis of tumors. The aim of this study is to assess the effects of perifosine, an inhibitor of Akt, on cell proliferation, apoptosis, angiogenesis, and VEGF-induced cell migration in cultured human umbilical vein endothelial cells (HUVECs) in vitro. MTT and cell cycle analysis results indicated that perifosine inhibited the growth of HUVECs in a dose-dependent manner, arrested cell cycle progression at the G(2) phase with regulation the expression of p21 and cyclinB1. Apoptosis induced by the higher concentrations of perifosine in HUVECs was also observed. In addition, tube formation of HUVECs and VEGF-induced cell migration were markedly inhibited by perifosine. Western blotting analysis of cell signaling molecules indicated that perifosine inhibited ERK and p38 phosphorylation in HUVECs. These results suggest that perifosine exerts anti-angiogenic activity in HUVECs and is a promising agent for treatment of angiogenesis related-diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21769450     DOI: 10.1007/s11010-011-0986-z

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  21 in total

Review 1.  Angiogenesis as a therapeutic target in urothelial carcinoma.

Authors:  Alvaro Pinto; Andrés Redondo; Pilar Zamora; Beatriz Castelo; Enrique Espinosa
Journal:  Anticancer Drugs       Date:  2010-11       Impact factor: 2.248

2.  The alkylphospholipid perifosine induces apoptosis and p21-mediated cell cycle arrest in medulloblastoma.

Authors:  Anil Kumar; Helen L Fillmore; Renu Kadian; William C Broaddus; Gary W Tye; Timothy E Van Meter
Journal:  Mol Cancer Res       Date:  2009-11-03       Impact factor: 5.852

3.  Randomized, double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer.

Authors:  R Leonard; J Hardy; G van Tienhoven; S Houston; P Simmonds; M David; J Mansi
Journal:  J Clin Oncol       Date:  2001-11-01       Impact factor: 44.544

4.  Sox9 sustains chondrocyte survival and hypertrophy in part through Pik3ca-Akt pathways.

Authors:  Daisuke Ikegami; Haruhiko Akiyama; Akira Suzuki; Takashi Nakamura; Toru Nakano; Hideki Yoshikawa; Noriyuki Tsumaki
Journal:  Development       Date:  2011-03-02       Impact factor: 6.868

5.  Factor XII stimulates ERK1/2 and Akt through uPAR, integrins, and the EGFR to initiate angiogenesis.

Authors:  Gretchen A LaRusch; Fakhri Mahdi; Zia Shariat-Madar; Gregory Adams; Robert G Sitrin; Wan Ming Zhang; Keith R McCrae; Alvin H Schmaier
Journal:  Blood       Date:  2010-03-12       Impact factor: 22.113

6.  Hispidulin, a small flavonoid molecule, suppresses the angiogenesis and growth of human pancreatic cancer by targeting vascular endothelial growth factor receptor 2-mediated PI3K/Akt/mTOR signaling pathway.

Authors:  Lijun He; Yuanyuan Wu; Lei Lin; Jieqiong Wang; Yougen Wu; Yihua Chen; Zhengfang Yi; Mingyao Liu; Xiufeng Pang
Journal:  Cancer Sci       Date:  2010-11-19       Impact factor: 6.716

Review 7.  Human umbilical vein endothelial cells and human dermal microvascular endothelial cells offer new insights into the relationship between lipid metabolism and angiogenesis.

Authors:  Ho-Jin Park; Yali Zhang; Serban P Georgescu; Kristin L Johnson; Dequon Kong; Jonas B Galper
Journal:  Stem Cell Rev       Date:  2006       Impact factor: 5.739

Review 8.  PI3K/PTEN signaling in angiogenesis and tumorigenesis.

Authors:  Bing-Hua Jiang; Ling-Zhi Liu
Journal:  Adv Cancer Res       Date:  2009       Impact factor: 6.242

Review 9.  PI3K/Akt signalling pathway specific inhibitors: a novel strategy to sensitize cancer cells to anti-cancer drugs.

Authors:  Marco Falasca
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

10.  Inhibition of MAPK kinase signaling pathways suppressed renal cell carcinoma growth and angiogenesis in vivo.

Authors:  Dan Huang; Yan Ding; Wang-Mei Luo; Stephanie Bender; Chao-Nan Qian; Eric Kort; Zhong-Fa Zhang; Kristin VandenBeldt; Nicholas S Duesbery; James H Resau; Bin Tean Teh
Journal:  Cancer Res       Date:  2008-01-01       Impact factor: 12.701

View more
  6 in total

1.  Vascular endothelial growth factor regulates primate choroid-retinal endothelial cell proliferation and tube formation through PI3K/Akt and MEK/ERK dependent signaling.

Authors:  Jing Jin; Fei Yuan; Min-qian Shen; Yi-fan Feng; Qi-liu He
Journal:  Mol Cell Biochem       Date:  2013-06-08       Impact factor: 3.396

2.  Therapeutic implications of targeting the PI3Kinase/AKT/mTOR signaling module in melanoma therapy.

Authors:  Ali R Jazirehi; Peter B Wenn; Mohsen Damavand
Journal:  Am J Cancer Res       Date:  2012-02-15       Impact factor: 6.166

3.  Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy.

Authors:  Daniel C Cho; Thomas E Hutson; Wolfram Samlowski; Peter Sportelli; Brad Somer; Paul Richards; Jeffrey A Sosman; Igor Puzanov; M Dror Michaelson; Keith T Flaherty; Robert A Figlin; Nicholas J Vogelzang
Journal:  Cancer       Date:  2012-06-06       Impact factor: 6.860

4.  Tumor-derived microvesicles induce proangiogenic phenotype in endothelial cells via endocytosis.

Authors:  Taisuke Kawamoto; Noritaka Ohga; Kosuke Akiyama; Naoya Hirata; Shuji Kitahara; Nako Maishi; Takahiro Osawa; Kazuyuki Yamamoto; Miyako Kondoh; Masanobu Shindoh; Yasuhiro Hida; Kyoko Hida
Journal:  PLoS One       Date:  2012-03-30       Impact factor: 3.240

5.  Effects of ionizing radiation in combination with Erufosine on T98G glioblastoma xenograft tumours: a study in NMRI nu/nu mice.

Authors:  Guido Henke; Verena Meier; Lars H Lindner; Hansjörg Eibl; Michael Bamberg; Claus Belka; Wilfried Budach; Verena Jendrossek
Journal:  Radiat Oncol       Date:  2012-10-18       Impact factor: 3.481

6.  Perifosine as a potential novel anti-telomerase therapy.

Authors:  Brody Holohan; Moriah M Hagiopian; Tsung-Po Lai; Ejun Huang; Daphne R Friedman; Woodring E Wright; Jerry W Shay
Journal:  Oncotarget       Date:  2015-09-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.